ZLAB Zai Lab Ltd. Sponsored ADR

Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference

Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference

SHANGHAI, China and SAN FRANCISCO, April 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that members of management will be presenting at the upcoming BofA Securities 2020 Health Care Conference. Presentation details for the virtual conference are as follows:

BofA Securities 2020 Health Care Conference

Presentation: Wednesday, May 13, 2020 at 9:00 a.m. ET

Presenter: Tao Fu, Chief Operating Officer

A live webcast of the company presentation will be available under "Events & Presentations" in the “Investors Relations” section of Zai Lab’s website. Archived replays will be available for approximately 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab

Billy Cho, CFO

01

Media: Ryo Imai / Robert Flamm, Ph.D.

Burns McClellan, on behalf of Zai Lab

212-213-0006 ext. 315 / 364

/

Investors: Pete Rahmer / Mike Zanoni

Endurance Advisors, on behalf of Zai Lab

415-515-9763 / 610-442-8570

/

Zai Lab Limited

EN
30/04/2020

Underlying

ZLABZai Lab Ltd. Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zai Lab Ltd. Sponsored ADR

Free Trial
ZLAB Zai Lab Ltd. Sp...

Zai Lab Limited: 2 directors

Two Directors at Zai Lab Limited sold after exercising options/sold 123,799 shares at between 29.533USD and 30.047USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...

ZLAB ZAI LAB LTD. SPONSORED ADR
05/14/25 May 14, 2025 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corp...

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER)VYVGART® (efgartigimod alfa injection) achieved $4.9 million sales since its commercial launch in September in ChinaStrong balance sheet with a cash position of $822.2 million as of September 30, 2023, compared to $876.4 million as of June 30, 2023Company to host conference call and webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mas...

November 7, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Announces Participation in November Investor Conferences SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023: Jefferies London Healthcare ConferenceFireside Chat: Wednesday, November 15th at 1:00 p.m. GMTLocation: London 6th Annual Evercore ISI HealthCONx ConferenceFireside Chat: Wednesday, November 29th at 1:45 p.m. ESTLocation: Miami A live webcast of the presentations will b...

October 26, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Co...

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023 - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on November 7, 2023. The Company will host a live conference call and webcast on November 8, 2023, at 8:00 a.m. ET. Conference Ca...

October 18, 2023 1 EN
 PRESS RELEASE
Free
ZLAB Zai Lab Ltd. Sp...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa...

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinatin...

September 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch